Activating alleles of JAK3 in acute megakaryoblastic leukemia.

Tyrosine kinases are aberrantly activated in numerous malignancies, including acute myeloid leukemia (AML). To identify tyrosine kinases activated in AML, we developed a screening strategy that rapidly identifies tyrosine-phosphorylated proteins using mass spectrometry. This allowed the identification of an activating mutation (A572V) in the JAK3 pseudokinase domain in the acute megakaryoblastic leukemia (AMKL) cell line CMK. Subsequent analysis identified two additional JAK3 alleles, V722I and P132T, in AMKL patients. JAK3(A572V), JAK3(V722I), and JAK3(P132T) each transform Ba/F3 cells to factor-independent growth, and JAK3(A572V) confers features of megakaryoblastic leukemia in a murine model. These findings illustrate the biological importance of gain-of-function JAK3 mutations in leukemogenesis and demonstrate the utility of proteomic approaches to identifying clinically relevant mutations.

[1]  J. Radich,et al.  The role of FLT3 in haematopoietic malignancies , 2003, Nature Reviews Cancer.

[2]  S. Ziegler,et al.  Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor. , 1993, Science.

[3]  Kimberly Lee,et al.  Phosphoproteomic analysis of AML cell lines identifies leukemic oncogenes. , 2006, Leukemia research.

[4]  J. O’Shea,et al.  JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants. , 2004, Trends in molecular medicine.

[5]  Stefan N. Constantinescu,et al.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera , 2005, Nature.

[6]  J. Rush,et al.  Immunoaffinity profiling of tyrosine phosphorylation in cancer cells , 2005, Nature Biotechnology.

[7]  J. Ihle,et al.  A Kinase-deficient Splice Variant of the Human JAK3 Is Expressed in Hematopoietic and Epithelial Cancer Cells (*) , 1995, The Journal of Biological Chemistry.

[8]  S. Orkin,et al.  Developmental stage–selective effect of somatically mutated leukemogenic transcription factor GATA1 , 2005, Nature Genetics.

[9]  A. Sharpe,et al.  Defects in B Lymphocyte Maturation and T Lymphocyte Activation in Mice Lacking Jak3 , 1995, Science.

[10]  J. Johnston,et al.  Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID. , 1994, Science.

[11]  T. Boggon,et al.  Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. , 2005, Blood.

[12]  M. Heinrich,et al.  An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  Z. Nagy,et al.  Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. , 2002, Blood.

[14]  Y. Minami,et al.  Critical role of the interleukin 2 (IL-2) receptor gamma-chain-associated Jak3 in the IL-2-induced c-fos and c-myc, but not bcl-2, gene induction. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[15]  L. Notarangelo,et al.  Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs , 2005, Immunological reviews.

[16]  D. Oscier,et al.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. , 2005, Blood.

[17]  F. Uckun,et al.  Targeting Janus Kinase 3 in Mast Cells Prevents Immediate Hypersensitivity Reactions and Anaphylaxis* , 1999, The Journal of Biological Chemistry.

[18]  E. Vellenga,et al.  Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts , 2000, Leukemia.

[19]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[20]  P. Doherty,et al.  Defective Lymphoid Development in Mice Lacking Jak3 , 1995, Science.

[21]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[22]  R. Berger,et al.  Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells. , 2000, Blood.

[23]  O. Silvennoinen,et al.  Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits. , 1994, Science.

[24]  Michael P. Brown,et al.  Reconstitution of early lymphoid proliferation and immune function in Jak3-deficient mice by interleukin-3. , 1999, Blood.

[25]  E. Liu,et al.  Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells , 1994, Nature.

[26]  T. Hirano,et al.  An alternative pathway for STAT activation that is mediated by the direct interaction between JAK and STAT , 1997, Oncogene.

[27]  J. Gustafsson,et al.  In vitro interaction between STAT 5 and JAK 2; dependence upon phosphorylation status of STAT 5 and JAK 2 , 1998, Molecular and Cellular Endocrinology.

[28]  J. Johnston,et al.  Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2 , 1994, Nature.

[29]  O. Silvennoinen,et al.  The Pseudokinase Domain Is Required for Suppression of Basal Activity of Jak2 and Jak3 Tyrosine Kinases and for Cytokine-inducible Activation of Signal Transduction* , 2002, The Journal of Biological Chemistry.

[30]  J. O’Shea,et al.  Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor , 2003, Science.

[31]  M. L. Beau,et al.  Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome , 2002, Nature Genetics.

[32]  Blake Middleton,et al.  Infectious Th1 and Th2 autoimmunity in diabetes‐prone mice , 1998, Immunological reviews.

[33]  J. Johnston,et al.  Regulation of JAK3 expression and activation in human B cells and B cell malignancies. , 1995, Journal of immunology.

[34]  M. Sliwkowski,et al.  Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor* , 2002, The Journal of Biological Chemistry.

[35]  Andrew D. Yates,et al.  Somatic mutations of the protein kinase gene family in human lung cancer. , 2005, Cancer research.

[36]  S. Meshinchi,et al.  Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia , 2005, Leukemia.

[37]  Manuel C. Peitsch,et al.  SWISS-MODEL: an automated protein homology-modeling server , 2003, Nucleic Acids Res..

[38]  M. Nerenberg,et al.  Constitutive activation of different Jak tyrosine kinases in human T cell leukemia virus type 1 (HTLV-1) tax protein or virus-transformed cells. , 1995, The Journal of clinical investigation.

[39]  L. Notarangelo,et al.  Complex Effects of Naturally Occurring Mutations in the JAK3 Pseudokinase Domain: Evidence for Interactions between the Kinase and Pseudokinase Domains , 2000, Molecular and Cellular Biology.

[40]  Stephen K Burley,et al.  A Novel Mode of Gleevec Binding Is Revealed by the Structure of Spleen Tyrosine Kinase* , 2004, Journal of Biological Chemistry.

[41]  T. Naoe,et al.  Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. , 2001, Blood.

[42]  J. O’Shea,et al.  A new modality for immunosuppression: targeting the JAK/STAT pathway , 2004, Nature Reviews Drug Discovery.

[43]  S. Constantinescu,et al.  JAK1 and Tyk2 Activation by the Homologous Polycythemia Vera JAK2 V617F Mutation , 2005, Journal of Biological Chemistry.

[44]  W. Leonard,et al.  Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. , 1995, Science.

[45]  Qingshan Li,et al.  Identification of an Acquired JAK2 Mutation in Polycythemia Vera* , 2005, Journal of Biological Chemistry.

[46]  D. Small,et al.  Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation , 2000, Leukemia.

[47]  M. Mann,et al.  Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. , 2003, Analytical chemistry.

[48]  M. Paul,et al.  Tyrosine kinase – Role and significance in Cancer , 2004, International journal of medical sciences.

[49]  T. Naoe,et al.  Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines , 1997, Leukemia.

[50]  Y. Hayashi,et al.  Establishment of a human leukaemic cell line (CMK) with megakaryocytic characteristics from a Down's syndrome patient with acute megakaryoblastic leukaemia , 1989, British journal of haematology.

[51]  M. Cetkovic-Cvrlje,et al.  Therapeutic potential of Janus kinase 3 (JAK3) inhibitors. , 2004, Current pharmaceutical design.

[52]  K. Liedl,et al.  Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. , 2001, Protein engineering.

[53]  S. Hubbard,et al.  Mechanism-based design of a protein kinase inhibitor , 2001, Nature Structural Biology.

[54]  R. Levine,et al.  Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. , 2006, Blood.

[55]  I. Weissman,et al.  Myeloerythroid-restricted progenitors are sufficient to confer radioprotection and provide the majority of day 8 CFU-S. , 2002, The Journal of clinical investigation.

[56]  B. Druker,et al.  RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518. , 2005, Blood.

[57]  Joshua E. Elias,et al.  Evaluation of multidimensional chromatography coupled with tandem mass spectrometry (LC/LC-MS/MS) for large-scale protein analysis: the yeast proteome. , 2003, Journal of proteome research.

[58]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[59]  B. Hall,et al.  Cells mediating allograft rejection. , 1991, Immunological reviews.

[60]  Daniela S Krause,et al.  Tyrosine kinases as targets for cancer therapy. , 2005, The New England journal of medicine.

[61]  F. Uckun,et al.  Targeting JAK3 with JANEX-1 for prevention of autoimmune type 1 diabetes in NOD mice. , 2003, Clinical immunology.

[62]  M. Vihinen,et al.  Mutations in severe combined immune deficiency (SCID) due to JAK3 deficiency , 2001, Human mutation.

[63]  T. Naoe,et al.  Differential constitutive activation between STAT‐related proteins and MAP kinase in primary acute myelogenous leukaemia , 1998, British journal of haematology.

[64]  R. Perlmutter,et al.  Requirement for Jak3 in mature T cells: its role in regulation of T cell homeostasis. , 1998, Journal of immunology.

[65]  Eugene C. Petrella,et al.  The Three-dimensional Structure of the ZAP-70 Kinase Domain in Complex with Staurosporine , 2004, Journal of Biological Chemistry.

[66]  J. Aster,et al.  Transformation of hematopoietic cell lines to growth‐factor independence and induction of a fatal myelo‐ and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes , 1998, The EMBO journal.